Volume 63, Issue 4, Pages (April 2003)

Slides:



Advertisements
Similar presentations
Dick de Zeeuw Department of Clinical Pharmacology University Medical Center Groningen The Netherlands Albuminuria; a tool for measuring non-blood pressure.
Advertisements

Optimization of pre-ESRD care: The key to improved dialysis outcomes
LDL cholesterol in CKD—to treat or not to treat?
Volume 54, Issue 2, Pages (August 1998)
Association Between Cardiac Biomarkers and the Development of ESRD in Patients With Type 2 Diabetes Mellitus, Anemia, and CKD  Akshay S. Desai, MD, MPH,
Anemia management in chronic kidney disease
Mitchell H. Rosner, W. Kline Bolton  Kidney International 
No difference in bleeding risk between subcutaneous enoxaparin and heparin for thromboprophylaxis in end-stage renal disease  Kevin E. Chan, Ravi I. Thadhani,
Volume 83, Issue 3, Pages (March 2013)
Anemia treatment in chronic kidney disease accompanied by diabetes mellitus or congestive heart failure  Steven Fishbane, Nobuyuki Miyawaki  Kidney International 
From secondary to primary prevention of progressive renal disease: The case for screening for albuminuria  Paul E. De Jong, Barry M. Brenner  Kidney International 
C-reactive protein and dialysis access
Volume 55, Issue 2, Pages (February 1999)
Volume 61, Issue 2, Pages (February 2002)
Chronic Kidney Disease in Diabetes
Volume 57, Issue 5, Pages (May 2000)
C-reactive protein and dialysis access
Risk of Progression of Nonalbuminuric CKD to End-Stage Kidney Disease in People With Diabetes: The CRIC (Chronic Renal Insufficiency Cohort) Study  Digsu.
Volume 54, Issue 2, Pages (August 1998)
Volume 86, Issue 4, Pages (October 2014)
Your Kidneys May Outlive You
Need for better diabetes treatment for improved renal outcome
Volume 66, Issue 3, Pages (September 2004)
Steven G. Coca, Swathi Singanamala, Chirag R. Parikh 
Volume 84, Issue 5, Pages (November 2013)
Comorbidity and confounding in end-stage renal disease
Volume 70, Issue 11, Pages (December 2006)
Volume 61, Issue 6, Pages (June 2002)
Renal risk scores: Progress and prospects
Volume 66, Pages S50-S55 (November 2004)
LDL cholesterol in CKD—to treat or not to treat?
Volume 71, Issue 6, Pages (March 2007)
Volume 70, Issue 12, Pages (December 2006)
Volume 67, Pages S48-S51 (January 2005)
Volume 65, Issue 6, Pages (June 2004)
Volume 69, Issue 9, Pages (May 2006)
Aggressive blood pressure reduction and renin–angiotensin system blockade in chronic kidney disease: time for re-evaluation?  Pantelis A. Sarafidis, Luis.
Volume 62, Issue 1, Pages (July 2002)
Should kidney donors be genotyped for APOL1 risk alleles?
Volume 76, Issue 3, Pages (August 2009)
Volume 66, Issue 2, Pages (August 2004)
Proteinuria and hypertensive nephrosclerosis in African Americans
Elevated risk of stroke among patients with end-stage renal disease
Volume 67, Issue 4, Pages (April 2005)
Volume 63, Issue 2, Pages (February 2003)
Counteracting progression of renal disease: A look into the future
Volume 74, Issue 5, Pages (September 2008)
Higher serum C-reactive protein predicts short and long-term outcomes in peritoneal dialysis-associated peritonitis  N.-Y. Zalunardo, C.-L. Rose, I.W.Y.
Volume 85, Issue 5, Pages (May 2014)
Homocysteine, renal function, and risk of cardiovascular disease
Increased dietary sodium is independently associated with greater mortality among prevalent hemodialysis patients  Finnian R. Mc Causland, Sushrut S.
Clinical renoprotection trials involving angiotensin II-receptor antagonists and angiotensin-converting-enzyme inhibitors  Barry M. Brenner, Joann Zagrobelny 
Kathy E. Sietsema, Antonino Amato, Sharon G. Adler, Eric P. Brass 
Low triiodothyronine and survival in end-stage renal disease
Volume 80, Issue 10, Pages (November 2011)
Volume 60, Issue 3, Pages (September 2001)
Michael R. Lattanzio, Matthew R. Weir  Kidney International 
Volume 65, Issue 4, Pages (April 2004)
Volume 60, Issue 6, Pages (December 2001)
Volume 64, Issue 4, Pages (October 2003)
Areef Ishani, Allan J. Collins, Charles A. Herzog, Robert N. Foley 
Volume 62, Pages S68-S72 (December 2002)
Yutaka Koda, M.D., Shin-Ichi Nishi, Masashi Suzuki, Yoshihei Hirasawa 
Volume 75, Issue 7, Pages (April 2009)
Changes to the End-Stage Renal Disease Quality Incentive Program
Volume 64, Issue 4, Pages (October 2003)
Volume 67, Issue 5, Pages (May 2005)
Optimization of pre-ESRD care: The key to improved dialysis outcomes
Volume 57, Pages S44-S48 (April 2000)
Volume 60, Issue 1, Pages (July 2001)
Presentation transcript:

Volume 63, Issue 4, Pages 1499-1507 (April 2003) The risk of developing end-stage renal disease in patients with type 2 diabetes and nephropathy: The RENAAL Study  William F. Keane, Barry M. Brenner, Dick de Zeeuw, Jean-Pierre Grunfeld, Janet McGill, William E. Mitch, Artur B. Ribeiro, Shahnaz Shahinfar, Roger L. Simpson, Steven M. Snapinn, Robert Toto, RENAAL Study Investigators  Kidney International  Volume 63, Issue 4, Pages 1499-1507 (April 2003) DOI: 10.1046/j.1523-1755.2003.00885.x Copyright © 2003 International Society of Nephrology Terms and Conditions

Figure 1 Kaplan-Meier estimates of event rate for doubling serum creatinine (DsCr) or end-stage renal disease (ESRD) stratified by quartiles. (A) Baseline urine albumin creatinine (Alb:Cr) ratio. The hazard ratio (HR) for each quartile was calculated and compared with that of the patients with the lowest values, who are in the reference quartile with a HR of 1.0. (—), Reference value Alb:Cr ratio>2.6 or>4.4 g protein/24 hours; (—), Alb:Cr ratio of 1.2 to 2.6 or 2.4 to 4.4 g protein/24 hours; (—), Alb:Cr ratio of 0.56 to 1.1 or 1.3 to 2.3 g protein/24 hours; (···), Alb:Cr ratio of <0.56 or <1.3 g protein/24 hours. (B) Baseline serum creatinine. The HR for each quartile was calculated and compared with that of the patients with the lowest values, who are in the reference quartile with a HR of 1.0. (—), Reference value of serum creatinine>2.1 mg/dL; (—), serum creatinine 1.8 to 2.1 mg/dL; (—), serum creatinine 1.5 to 1.7 mg/dL; (···), serum creatinine <1.5 mg/dL). (C) Baseline serum albumin. The HR for each quartile was calculated and compared with that of the patients with the highest values, who are in the reference quartile with a HR of 1.0. (···), Reference value of serum albumin <3.6 g/dL; (—), serum albumin 3.6 to 3.8 g/dL; (—), serum albumin 3.9 to 4.0 g/dL; (—) serum albumin>4.0 g/dL. (D) Baseline hemoglobin. The HR for each quartile was calculated and compared with that of the patients with the highest values, who are in the reference quartile with a HR of 1.0. (···), Reference value of hemoglobin <11.2 g/dL; (—), hemoglobin 12.4 to 11.2 g/dL; (—), hemoglobin 13.8 to 12.5 g/dL; (—), hemoglobin>13.8 g/dL. Kidney International 2003 63, 1499-1507DOI: (10.1046/j.1523-1755.2003.00885.x) Copyright © 2003 International Society of Nephrology Terms and Conditions